# Oramed Pharmaceuticals Inc.: overview ORMP · Nasdaq · CIK 1176309 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ormp.md) · [Financials](/companies/ormp/financials.md) · [Filings](/companies/ormp/filings.md) · [Insiders](/companies/ormp/insiders.md) Latest reported revenue: [$0](/filings/0001213900-26-034835.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 26, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-034835). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | [2,000](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | not reported | not reported | | Gross margin | % | not reported | not reported | [0.7%](/filings/0001213900-26-059112.md) | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(225.0%)](/filings/0001213900-26-059112.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | [(382.1%)](/filings/0001213900-26-059112.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.48)](/filings/0001213900-25-109980.md) | not reported | [(0.19)](/filings/0001213900-26-059112.md) | [0.31](/filings/0001213900-26-087361.md) | [1.13](/filings/0001213900-25-109980.md) | not reported | [0.91](/filings/0001213900-26-059112.md) | [1.84](/filings/0001213900-26-087361.md) | | Free cash flow | $k | [(7,106) d](/filings/0001213900-25-109980.md) | [(1,922) d](/filings/0001213900-26-034835.md) | [(3,522)](/filings/0001213900-26-059112.md) | [(3,539) d](/filings/0001213900-26-087361.md) | [(1,625) d](/filings/0001213900-25-109980.md) | [(468) d](/filings/0001213900-26-034835.md) | [(2,920)](/filings/0001213900-26-059112.md) | [(202) d](/filings/0001213900-26-087361.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-08-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.7](/filings/0001213900-21-062009.md) | [2.7](/filings/0001213900-24-020485.md) | [1.3](/filings/0001013762-25-003450.md) | not reported | [2.0](/filings/0001213900-26-034835.md) | | Gross margin | % | not reported | not reported | not reported | not reported | [0.7%](/filings/0001213900-26-034835.md) | | Operating margin | % | [(896.2%)](/filings/0001213900-21-062009.md) | [(1502.0%)](/filings/0001213900-24-020485.md) | [(1176.8%)](/filings/0001013762-25-003450.md) | not reported | [(754.4%)](/filings/0001213900-26-034835.md) | | Net margin | % | [(850.5%)](/filings/0001213900-21-062009.md) | [(1352.6%)](/filings/0001213900-24-020485.md) | [379.7%](/filings/0001013762-25-003450.md) | not reported | [3202.5%](/filings/0001213900-26-034835.md) | | Diluted EPS | $ per share | [0.78](/filings/0001213900-21-062009.md) | [(0.94)](/filings/0001213900-24-020485.md) | [0.14](/filings/0001013762-25-003450.md) | [(0.48)](/filings/0001213900-26-034835.md) | [1.50](/filings/0001213900-26-034835.md) | | Free cash flow | $m | [(21.6)](/filings/0001213900-23-017837.md) | [(28.4)](/filings/0001213900-24-020485.md) | [(10.5)](/filings/0001013762-25-003450.md) | [(8.4)](/filings/0001213900-26-034835.md) | [(9.2)](/filings/0001213900-26-034835.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ormp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MERCER GLOBAL ADVISORS INC /ADV](/funds/853758.md) | 2026-06-30 | $18.3m | 3,810,540 | | Added +1,900,000 | | [Aquamarine Financial (Cayman) Ltd](/funds/2104187.md) | 2026-06-30 | $12.1m | 2,512,175 | | Added +399,863 | | [Gem Investment Advisors, LLC](/funds/1580018.md) | 2026-06-30 | $9.6m | 1,998,802 | | Added +358,733 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.7m | 1,608,111 | | Added +1,515,919 | | [Murchinson Ltd.](/funds/1838556.md) | 2026-06-30 | $6.2m | 1,290,294 | | Reduced −25,000 | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $4.2m | 866,269 | | Reduced −2,300,962 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $2.8m | 578,638 | | Reduced −22,078 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.4m | 500,690 | | Added +476,408 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.2m | 253,293 | | New +253,293 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.2m | 242,100 | | New +242,100 | ## Recent filings [All 809 filings](/companies/ormp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-17 | 19:37 ET | [8-K](/filings/0001213900-26-100929.md) | 5.07 Shareholder vote results | 0001213900-26-100929 | | 2026-08-10 | 21:29 ET | [10-Q](/filings/0001213900-26-087361.md) | Quarterly report, period 2026-06-30 | 0001213900-26-087361 | | 2026-08-03 | 20:05 ET | [DEF 14A](/filings/0001213900-26-084609.md) | Proxy statement, period 2026-09-15 | 0001213900-26-084609 | | 2026-07-22 | 16:15 ET | [SCHEDULE 13D/A](/filings/0001213900-26-080406.md) | Ownership report, active investor, amended | 0001213900-26-080406 | | 2026-06-30 | 20:19 ET | [8-K](/filings/0001213900-26-073709.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-073709 | | 2026-06-17 | 20:48 ET | [SCHEDULE 13D/A](/filings/0001213900-26-069783.md) | Ownership report, active investor, amended | 0001213900-26-069783 | | 2026-05-19 | 21:08 ET | [10-Q](/filings/0001213900-26-059112.md) | Quarterly report, period 2026-03-31 | 0001213900-26-059112 | | 2026-05-14 | 17:19 ET | [SCHEDULE 13D](/filings/0001213900-26-056837.md) | Ownership report, active investor | 0001213900-26-056837 | | 2026-03-31 | 20:20 ET | [8-K](/filings/0001213900-26-037474.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition | 0001213900-26-037474 | | 2026-03-26 | 21:14 ET | [10-K](/filings/0001213900-26-034835.md) | Annual report, period 2025-12-31 | 0001213900-26-034835 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-034835.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1176309 - Tickers: ORMP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.